WHO ICTRP trial
Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once…
NL-OMON36312 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON36312 |
|---|---|
| Public title | Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting. |
| Scientific title | Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting. - BASAAL PLUS |
| Primary sponsor | Sanofi-aventis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Observational invasive |
| Phase | 4 |
| Countries | Netherlands |
| Conditions | Diabetes type 2;10018424;Diabetes type 2 |
| Interventions | ;Diabetes Mellitus type 2;Insulin glargine;Insulin glulisine;Normoglycemia |
| Registration date | Jun 16, 2011 |
| Target size | 220 |
| Secondary IDs | 2009-015742-34;NCT01079364;NL30289.040.09 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: